New combo therapy 'effective first line in advanced renal cancer'

The first results of the CheckMate 9ER trial show a good response rate and improved survival, researchers say

AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.

A checkpoint inhibitor partnered with a targeted chemotherapy agent could be a new first-line option for patients with advanced renal cell carcinoma, a leading oncologist says.

The first results of the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib showed improved survival over 18 months compared with the standard of care, sunitinib, said Dr Toni Choueiri,